Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14369395 | 0.90 | GSK3B (0.62) | GSK3BMAPTL3MBTL1GAATHRA | |
| SCHEMBL13299300 | 0.89 | GSK3B (0.60) | GSK3BMAPTL3MBTL1PTPN1THRA | |
| SCHEMBL864323 | 0.84 | MAPT (0.58) | MAPTL3MBTL1RAB9AGAAPLK1 | |
| SCHEMBL5057170 | 0.84 | L3MBTL1 (0.70) | GSK3BMAPTL3MBTL1PTPN1PLK1 | |
| SCHEMBL5055145 | 0.84 | L3MBTL1 (0.65) | GSK3BMAPTL3MBTL1THRA | |
| SCHEMBL16806634 | 0.84 | GSK3B (0.68) | GSK3BMAPTRAB9APTPN1 | |
| SCHEMBL23929839 | 0.83 | GSK3B (0.57) | GSK3BMAPTL3MBTL1RAB9APTPN1 | |
| SCHEMBL5744957 | 0.83 | THRA (0.65) | GSK3BMAPTL3MBTL1PTPN1PKM | |
| SCHEMBL9786122 | 0.82 | GSK3B (0.59) | GSK3BMAPTL3MBTL1PTPN1PKM | |
| SCHEMBL13108708 | 0.82 | MAPT (0.63) | MAPTL3MBTL1RAB9APKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279231-A1 | MAP4K4 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-08-22 | — | — | US | disclosed |
| US-7759349-B2 | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1699799-B1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES | SCHERING PLOUGH LTD (CH) | 2007-05-16 | — | — | EP | disclosed |
| EP-1699799-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES | Schering-Plough Ltd. (CH) | 2006-09-13 | — | — | EP | disclosed |
| EP-0842923-B1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU CO LTD (JP) | 2006-03-01 | — | — | EP | disclosed |
| US-20050182059-A1 | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2005-08-18 | — | — | US | disclosed |
| WO-2005066177-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | SCHERING-PLOUGH LTD. (CH) | 2005-07-21 | — | — | WO | disclosed |
| CN-1349796-A | Pyrrole derivatives and medicine composition | NIPPON SHINYAKU CO LTD (JP) | 2002-05-22 | — | — | CN | disclosed |
| US-6172102-B1 | POLLAKIURIA OR URINARY INCONTINENCE | NIPPON SHINYAKU CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-5998459-A | INCOTINENCE THERAPY | NIPPON SHINYAKU CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0842923-A1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279231-A1 | MAP4K4 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | MAP4K4, MAP4K2, MAPK4 | GSK3B 677/4885MAPT 141/4885L3MBTL1 4474/4885 |
| US-20050182059-A1 | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives | PLPBP, PIR, PPIP5K2 | GSK3B 4620/4885MAPT 4648/4885L3MBTL1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.